ClinicalTrials.Veeva

Menu

Sensory Rehabilitation in Chemo Induced Peripheral Neuropathy

S

Shamir Medical Center (Assaf-Harofeh)

Status

Not yet enrolling

Conditions

Chemotherapy-induced Peripheral Neuropathy
CIPN - Chemotherapy-Induced Peripheral Neuropathy
Age Over 18

Treatments

Other: no treatment
Other: Explicit Sensory Retraining for the lower extremities

Study type

Interventional

Funder types

Other

Identifiers

NCT06724861
CIPN - RCT

Details and patient eligibility

About

This study is a cross-over RCT evaluating the effectiveness of 3 sessions a week apart of explicit sensory retraining to the lower extremities in individuals with CIPN versus usual care. The primary outcome measures are TNAS for subjective symptoms, VAS for pain and TUG for mobility. Additional outcome measures are FABS for balance, sensory assessments - monofilaments for touch threshold, LEPT for proprioception, a home exercise log and a satisfaction questionnaire.

Full description

Chemotherapy Induced Peripheral Neuropathy (CIPN) is a neurological complication of chemotherapy, affecting between 50%-90% of the patients: up to 68% within the first month after chemotherapy, 60% after 3 months, and 30% after 6 months.

Neuropathic symptoms can persist in 11% to more than 80% of individuals post chemotherapy at one to three years following treatment and around 50% even after 5 years and more.

CIPN is associated with lower self-reported physical function and Quality of Life (QoL).

The clinical picture is typically sensory, with involvement of large and small sensory fibers. Motor and autonomic involvement is less frequent.

Damage to sensory nerve fibers is typically symmetrical. Sensory loss in a 'glove and stocking type' distribution leads to 'minus' symptoms (loss of function) including numbness in hands and feet, impaired perception of light touch, hypoalgesia and impaired proprioception, temperature and vibration sensation. Paradoxically, 'plus' features (gain of function) such as paresthesia (tingling like pins and needles), dysesthesia, allodynia and hyperalgesia appear simultaneously. CIPN can be functionally debilitating including impaired balance, walking slower and shorter steps and increased falls.

Active, explicit sensory rehabilitation is efficient in promoting sensation and function in individuals with neurological conditions, such as stroke and multiple sclerosis. To the best of our knowledge although CIPN is primarily a sensory deficit there is no treatment aimed at this aspect. We aim to conduct a pilot study to explore the feasibility and clinical benefit of an active, explicit sensory rehabilitation protocol for the lower limb in individuals with chronic CIPN.

This study is a cross-over RCT evaluating the effectiveness of 3 sessions a week apart of explicit sensory retraining to the lower extremities in individuals with CIPN versus usual care. The primary outcome measures are TNAS for subjective symptoms, VAS for pain and TUG for mobility. Additional outcome measures are FABS for balance, sensory assessments - monofilaments for touch threshold, LEPT for proprioception, a home exercise log and a satisfaction questionnaire.

Enrollment

27 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • CIPN by self-report (present or absent) > 3 months after last chemotherapy treatment
  • age > 18.

Exclusion criteria

  • Pre-chemotherapy neuropathy/ sensory impairment
  • recurrent falls prior to chemotherapy (more than 2 per year)
  • CNS involvement
  • not ambulatory before chemotherapy
  • Hebrew proficiency not meeting questionnaires' needs.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Double Blind

27 participants in 2 patient groups

AB - early experimental treatment, later control usual care
Other group
Description:
AB - early experimental treatment, later control usual care
Treatment:
Other: Explicit Sensory Retraining for the lower extremities
Other: no treatment
BA - early control usual care, later experimental treatment
Other group
Description:
BA - early control usual care, later experimental treatment
Treatment:
Other: Explicit Sensory Retraining for the lower extremities
Other: no treatment

Trial contacts and locations

1

Loading...

Central trial contact

Rotem Merose, MD; Hadas Ofek, PT, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems